Three Levers on One System
The body releases growth hormone (GH) in pulses from the pituitary gland, under the push-and-pull of two hypothalamic signals: growth-hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which suppresses it. A third natural signal, the stomach-derived hormone ghrelin, also stimulates GH release through its own receptor. Almost every GH-oriented research compound works by imitating one of these signals.
There are effectively three levers. The first is the GHRH lever, pulled by GHRH analogs. The second is the ghrelin lever, pulled by peptide GH-releasing peptides (GHRPs) and their non-peptide cousins. The third is a special case of the second: MK-677, an orally active molecule that pulls the ghrelin lever without an injection.
GHRH Analogs: Sermorelin, CJC-1295, Tesamorelin
GHRH analogs are synthetic versions of natural GHRH or its active fragment. They bind the pituitary GHRH receptor and stimulate the synthesis and pulsatile release of the body's own growth hormone. Because they amplify a natural pulse rather than replacing GH outright, they are often described as preserving the normal rhythm of GH secretion. Sermorelin corresponds to the first 29 amino acids of GHRH; CJC-1295 is a modified GRF(1-29) engineered for greater stability, and its with-DAC version adds a drug-affinity complex that extends its half-life to around a week.
Tesamorelin is the standout of this group because it is an actual approved drug: marketed as Egrifta, it is FDA-approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. Sermorelin was itself previously approved (as Geref) and withdrawn for commercial rather than safety reasons; it remains available through compounding channels. CJC-1295 has no such approval and is sold strictly as a research compound.
GHRPs and Ghrelin-Receptor Secretagogues
GHRPs — growth-hormone-releasing peptides — act not on the GHRH receptor but on the growth-hormone secretagogue receptor (GHS-R1a), the same receptor that ghrelin uses. In addition to stimulating GH release directly, they blunt somatostatin, effectively releasing the brake at the same time they press the accelerator. Ipamorelin is the most frequently discussed because it is relatively selective, reported to release GH with comparatively little effect on cortisol or prolactin; GHRP-2 and GHRP-6 are older, stronger secretagogues, with GHRP-6 in particular known for a pronounced hunger-stimulating effect.
The reason GHRH analogs and GHRPs are so often paired — the classic example being CJC-1295 with ipamorelin — is that pulling two different levers produces a larger, well-documented synergistic GH release than pulling either alone. In research settings these are described in microgram amounts (ipamorelin is often cited around 100 to 300 mcg per administration, subcutaneously), typically timed to a fasted state — but again these are reported observations rather than recommendations.
MK-677 (Ibutamoren): The Oral Outlier
MK-677 (ibutamoren) pulls the same ghrelin lever as the GHRPs, but it is not a peptide at all — it is an orally active, non-peptide molecule with a long half-life of roughly 24 hours, which is why it is taken once daily by mouth rather than injected. In trials it produces sustained increases in GH and IGF-1. Its convenience is also its complication: a durable, round-the-clock elevation of a ghrelin-like signal drives a distinctive set of caveats that the pulsatile injectables produce to a lesser degree.
- Increased appetite: as a ghrelin mimetic, MK-677 commonly stimulates hunger — useful in some research contexts, unwanted in others.
- Water retention and edema: fluid retention and joint discomfort are frequently reported, especially early on.
- Reduced insulin sensitivity: trials report increased fasting blood glucose and lowered insulin sensitivity, a meaningful metabolic consideration.
- Lethargy and elevated IGF-1: some report tiredness; sustained IGF-1 elevation is the intended effect but also the source of several concerns.
Combining the Levers, and Regulatory Status
The practical logic of combining these compounds follows from the three-lever model: a GHRH analog and a ghrelin-receptor agonist hit different receptors and synergize, whereas stacking two compounds that pull the same lever mostly adds redundancy and side effects. This is why GHRH-plus-GHRP pairings dominate the discussion, and why adding MK-677 on top of a GHRP is often questioned — they compete for the same receptor. MK-677 has been studied in humans more than most compounds here, but those studies surfaced concerns too; a trial in frail elderly patients raised a congestive-heart-failure signal that ended development for that indication.
Regulatory status varies sharply within the group. Tesamorelin is an approved drug; sermorelin is a formerly approved drug still available through compounding; CJC-1295, ipamorelin, the GHRP-2/6 family, and MK-677 are not approved and are sold as research chemicals. All of them are prohibited in sport under WADA (S2). Nothing here is medical advice; it is an explanation of how these research compounds are categorized and studied.